Platinol-AQ (Intravenous)
Generic name:cisplatin (intravenous route) [ sis-PLA-tin ]
Drug class:Alkylating agents
Medically reviewed by Drugs.com. Last updated on Apr 26, 2022.
Nephrotoxicity: cisplatin injection can cause severe renal toxicity, including acute renal failure. Severe renal toxicities are dose-related and cumulative. Consider dose reductions or alternative treatments in patients with renal impairment.Peripheral Neuropathy: cisplatin injection can cause dose-related peripheral neuropathy.Nausea and Vomiting: cisplatin injection can cause severe nausea and vomiting. Premedicate with antiemetics.Myelosuppression: cisplatin injection can cause severe myelosuppression with fatalities due to infections. Monitor blood counts and interrupt therapy accordingly .
The Platinol-AQ brand name has been discontinued in the U.S. If generic versions of this product have been approved by the FDA, there may be generic equivalents available.
Commonly used brand name(s)
In the U.S.
- Platinol-AQ
Available Dosage Forms:
- Powder for Solution
- Solution
Therapeutic Class: Antineoplastic Agent
Pharmacologic Class: Platinum Coordination Complex
Uses for Platinol-AQ
Cisplatin injection is used to treat advanced cancer of the bladder, ovaries, or testicles.
Cisplatin is an antineoplastic agent (cancer medicine). It interferes with the growth of cancer cells, which are eventually destroyed by the body.
This medicine is to be given only by or under the direct supervision of a doctor.
Before using Platinol-AQ
In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For this medicine, the following should be considered:
Allergies
Tell your doctor if you have ever had any unusual or allergic reaction to this medicine or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.
Pediatric
Appropriate studies have not been performed on the relationship of age to the effects of cisplatin injection in the pediatric population. Safety and efficacy have not been established. This medicine may increase the risk for serious ear or hearing problems in children younger that 5 years of age.
Geriatric
Appropriate studies performed to date have not demonstrated geriatric-specific problems that would limit the usefulness of cisplatin injection in the elderly. However, elderly patients are more likely to have age-related kidney disease or unwanted effects (eg, nerve problems, blood or bone marrow problems), which may require caution and an adjustment in the dose for patients receiving this medicine.
Breastfeeding
There are no adequate studies in women for determining infant risk when using this medication during breastfeeding. Weigh the potential benefits against the pot..
